SOAT1 and rheumatoid arthritis: Over the last decade, JAK inhibitors, small molecules that target the JAK-STAT signaling pathway, have been developed as targeted synthetic disease–modifying antirheumatic drugs (tsDMARDs) for immune-mediated inflammatory diseases (IMIDs) such as rheumatoid arthritis (RA) [3–5].